title: Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique.
abstract: In order to reduce the severe venous toxicity, we developed an intravenous lipid emulsion of vinorelbine and investigated its preclinical stability, toxicity and antitumor efficacy. Vinorelbine-phospholipid complex was prepared to enhance the lipophilicity of vinorelbine thus facilitating the encapsulation into lipid emulsion. After complexation more than 70% of vinorelbine was encapsulated into the oil phase. Meanwhile, the lipid emulsion showed good stability without drug leakage. Local irritation after injection of the lipid emulsion was investigated in rabbits and compared with Navelbine(®) (the commercial product). The antitumor therapeutic efficacies were evaluated in tumor-bearing mouse models inoculated with A549 human lung cancer cells and BCAP-37 human breast cancer cells and compared as well. Results showed that the lipid emulsion significantly reduced the injection irritation compared with that of Navelbine(®), while maintained the antitumor activity in A549 and BCAP-37 cells xenograft tumor mouse models. Taken together, lipid emulsion loaded with vinorelbine-phospholipid complex is a promising vinorelbine intravenous injection with reduced venous irritation.
authors.affiliation: State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, No. 308, Anshan Road, Tianjin 300193, People's Republic of China.
authors.forename: Yanzhen
authors.initials: Y
authors.lastname: Li
authors.forename: Wenxian
authors.initials: W
authors.lastname: Jin
authors.forename: Hui
authors.initials: H
authors.lastname: Yan
authors.forename: Huan
authors.initials: H
authors.lastname: Liu
authors.forename: Chenggang
authors.initials: C
authors.lastname: Wang
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002152:Calorimetry, Differential Scanning; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical; D018360:Crystallography, X-Ray; D004337:Drug Carriers; D004355:Drug Stability; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage / Q000737:chemistry* / Q000633:toxicity; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D010743:Phospholipids / Q000008:administration & dosage / Q000737:chemistry* / Q000633:toxicity; D011817:Rabbits; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D014680:Veins / Q000187:drug effects / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D000077235:Vinorelbine; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D005217:Fat Emulsions, Intravenous; D010743:Phospholipids; D014747:Vinblastine; D000077235:Vinorelbine
keywords: Antitumor activity; Drug–phospholipid complex; Injection irritation; Vinorelbine